Evidence map›Paper›PMID 36054452›Full record

ArticleJournal for immunotherapy of cancer2022

Single-cell transcriptomics reveals shared immunosuppressive landscapes of mouse and human neuroblastoma.

Ana Costa, Cécile Thirant, Amira Kramdi, Cécile Pierre-Eugène, Caroline Louis-Brennetot, Orphée Blanchard, Didier Surdez, Nadege Gruel, Eve Lapouble, Gaëlle Pierron and 19 more

Open access · goldAbstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Transcriptomic Association of COL3A1Pain research & management · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Reprogramming the neuroblastoma tumor immune microenvironment to enhance GPC2 CAR T cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 3 institutions in 1 country.

Ana CostaInserm U830, Equipe Labellisée LNCC, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Institut Curie Research Centre, Paris, France.ORCID 0000-0002-0893-3388
Cécile ThirantInserm U830, Equipe Labellisée LNCC, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Institut Curie Research Centre, Paris, France.ORCID 0000-0003-3873-5240
Amira KramdiInserm U830, Equipe Labellisée LNCC, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Institut Curie Research Centre, Paris, France.
Cécile Pierre-EugèneInserm U830, Equipe Labellisée LNCC, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Institut Curie Research Centre, Paris, France.
Caroline Louis-BrennetotInserm U830, Equipe Labellisée LNCC, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Institut Curie Research Centre, Paris, France.
Orphée BlanchardInserm U830, Equipe Labellisée LNCC, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Institut Curie Research Centre, Paris, France.
Didier SurdezInserm U830, Equipe Labellisée LNCC, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Institut Curie Research Centre, Paris, France.
Nadege GruelInserm U830, Equipe Labellisée LNCC, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Institut Curie Research Centre, Paris, France.
Eve LapoubleUnité de Génétique Somatique, Institut Curie, Paris, France.
Gaëlle PierronUnité de Génétique Somatique, Institut Curie, Paris, France.
Deborah SitbonUnité de Génétique Somatique, Institut Curie, Paris, France.
Hervé BrisseDepartment of Imaging, PSL Research University, Institut Curie, Paris, France.
Arnaud GauthierDepartment of Biopathology, Institut Curie, Paris, France.
Paul FréneauxDepartment of Biopathology, Institut Curie, Paris, France.
Mylène BohecGenomics of Excellence (ICGex) Platform, Institut Curie, Paris, France.
Virginie RaynalInserm U830, Equipe Labellisée LNCC, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Institut Curie Research Centre, Paris, France.
Sylvain BaulandeGenomics of Excellence (ICGex) Platform, Institut Curie, Paris, France.
Renaud LeclereDepartment of Biopathology, Institut Curie, Paris, France.
Gabriel ChampenoisDepartment of Biopathology, Institut Curie, Paris, France.
Andre NicolasDepartment of Biopathology, Institut Curie, Paris, France.
Didier MeseureDepartment of Biopathology, Institut Curie, Paris, France.
Angela BelliniSIREDO: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France.
Aurelien MarabelleInserm U1015 & CIC1428, Université Paris Saclay, Gustave Roussy, Villejuif, France.ORCID 0000-0002-5816-3019
Birgit GeoergerInserm U1015, Department of Pediatric and Adolescent Oncology, Université Paris-Saclay, Gustave Roussy, Villejuif, France.
Fatima Mechta-GrigoriouInserm U830, Equipe labelisée LNCC, Stress and Cancer Laboratory, PSL Research University, Institut Curie Research Centre, Paris, France.
Gudrun SchleiermacherSIREDO: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France.
Laurie MengerInserm U932, PSL Research University, Institut Curie, Paris, France.
Olivier DelattreInserm U830, Equipe Labellisée LNCC, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Institut Curie Research Centre, Paris, France.
Isabelle Janoueix-LeroseyInserm U830, Equipe Labellisée LNCC, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Institut Curie Research Centre, Paris, France janoueix@curie.fr.ORCID 0000-0003-0434-3003
Inserm · FRInstitut Curie · FRUniversité Paris Sciences et Lettres · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHigh-risk neuroblastoma is a pediatric cancer with still a dismal prognosis, despite multimodal and intensive therapies. Tumor microenvironment represents a key component of the tumor ecosystem the complexity of which has to be accurately understood to define selective targeting opportunities, including immune-based therapies.

methodsWe combined various approaches including single-cell transcriptomics to dissect the tumor microenvironment of both a transgenic mouse neuroblastoma model and a cohort of 10 biopsies from neuroblastoma patients, either at diagnosis or at relapse. Features of related cells were validated by multicolor flow cytometry and functional assays.

resultsWe show that the immune microenvironment of MYCN-driven mouse neuroblastoma is characterized by a low content of T cells, several phenotypes of macrophages and a population of cells expressing signatures of myeloid-derived suppressor cells (MDSCs) that are molecularly distinct from the various macrophage subsets. We document two cancer-associated fibroblasts (CAFs) subsets, one of which corresponding to CAF-S1, known to have immunosuppressive functions. Our data unravel a complex content in myeloid cells in patient tumors and further document a striking correspondence of the microenvironment populations between both mouse and human tumors. We show that mouse intratumor T cells exhibit increased expression of inhibitory receptors at the protein level. Consistently, T cells from patients are characterized by features of exhaustion, expressing inhibitory receptors and showing low expression of effector cytokines. We further functionally demonstrate that MDSCs isolated from mouse neuroblastoma have immunosuppressive properties, impairing the proliferation of T lymphocytes.

conclusionsOur study demonstrates that neuroblastoma tumors have an immunocompromised microenvironment characterized by dysfunctional T cells and accumulation of immunosuppressive cells. Our work provides a new and precious data resource to better understand the neuroblastoma ecosystem and suggest novel therapeutic strategies, targeting both tumor cells and components of the microenvironment.

Indexed as

NeuroblastomaTranscriptomeAnimalsChildEcosystemHumansMiceNeoplasm Recurrence, LocalTumor MicroenvironmentGene Expression ProfilingMacrophagesMyeloid-Derived Suppressor CellsNeuroblastomaTumor Microenvironment

Identifiers

PMID36054452
PMCPMC9362821
OpenAlexW4293233306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.